{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5"}]}],"title":"Grade II acute GVHD (moderate)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5"}]}],"title":"Grade III (moderate) or IV (severe) acute GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Severe chronic GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"GVHD was graded according to standard criteria as referred to in the reference module (Filipovich et al. 2005; Przepiorka et al. 1995).","groups":[{"description":"Donor lymphocyte preparation depleted of host functional alloreactive T-cells: Single intravenous infusion with 2x10E6 T-cells/kg","id":"OG000","title":"ATIR"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 24 months after the transplantation","title":"Incidence and Severity Graft-versus-host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}